A detailed history of Norris Perne & French LLP transactions in Opko Health, Inc. stock. As of the latest transaction made, Norris Perne & French LLP holds 27,000 shares of OPK stock, worth $39,150. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,000
Previous 25,000 8.0%
Holding current value
$39,150
Previous $31,000 29.03%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

BUY
$1.21 - $1.68 $2,420 - $3,360
2,000 Added 8.0%
27,000 $40,000
Q2 2023

Jul 19, 2023

BUY
$1.37 - $2.17 $6,850 - $10,850
5,000 Added 25.0%
25,000 $54,000
Q1 2023

Apr 20, 2023

SELL
$1.06 - $1.61 $39,220 - $59,570
-37,000 Reduced 64.91%
20,000 $29,000
Q4 2022

Jan 24, 2023

SELL
$1.05 - $2.01 $9,450 - $18,089
-9,000 Reduced 13.64%
57,000 $0
Q2 2022

Aug 11, 2022

SELL
$2.33 - $3.61 $2,330 - $3,610
-1,000 Reduced 1.49%
66,000 $167,000
Q3 2021

Oct 26, 2021

BUY
$3.44 - $4.24 $24,080 - $29,680
7,000 Added 11.67%
67,000 $245,000
Q1 2021

Apr 30, 2021

BUY
$4.19 - $5.99 $2,095 - $2,995
500 Added 0.84%
60,000 $257,000
Q4 2020

Jan 27, 2021

BUY
$3.27 - $4.87 $22,890 - $34,090
7,000 Added 13.33%
59,500 $235,000
Q3 2020

Oct 26, 2020

BUY
$2.99 - $5.96 $1,495 - $2,980
500 Added 0.96%
52,500 $194,000
Q2 2020

Jul 23, 2020

BUY
$1.15 - $3.41 $21,275 - $63,085
18,500 Added 55.22%
52,000 $177,000
Q1 2020

Apr 16, 2020

BUY
$1.34 - $2.32 $26,800 - $46,400
20,000 Added 148.15%
33,500 $45,000
Q4 2019

Jan 22, 2020

BUY
$1.42 - $2.17 $19,170 - $29,295
13,500 New
13,500 $20,000
Q4 2017

Jan 23, 2018

SELL
$4.61 - $7.04 $46,561 - $71,104
-10,100 Closed
0 $0
Q3 2017

Nov 01, 2017

BUY
$5.88 - $7.11 $59,388 - $71,811
10,100
10,100 $69,000

Others Institutions Holding OPK

About OPKO HEALTH, INC.


  • Ticker OPK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 771,960,000
  • Market Cap $1.12B
  • Description
  • OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and...
More about OPK
Track This Portfolio

Track Norris Perne & French LLP Portfolio

Follow Norris Perne & French LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norris Perne & French LLP, based on Form 13F filings with the SEC.

News

Stay updated on Norris Perne & French LLP with notifications on news.